ProBio Inc., a New Jersey-based contract development and manufacturing organization (CDMO), has expanded its plasmid DNA and viral vector manufacturing capabilities with the opening of a new facility in Hopewell, New Jersey.
 
This facility will serve as the hub for North American operations, significantly enhancing ProBio’s capability to support the manufacturing of cell and gene therapies in North America.
 
The Hopewell facility spans approximately 128,000 square feet; it encompasses office, laboratory, and manufacturing spaces outfitted with the latest equipment and technology for process development and current good manufacturing practice (cGMP) production of plasmid DNA and viral vectors, including adeno-associated virus, lentivirus, and retrovirus.
 
This site supports tech transfer, method and analytical development, process development, drug substance, drug product manufacturing for both clinical and commercial-grade plasmid DNA and viral vector-based therapies. All operations are maintained with rigorous quality control and quality assurance processes.
 
“We are proud to expand our capabilities to manufacture life-changing biologic drugs to the growing cell and gene therapy industry. Our dedicated, talented team and state-of-the-art manufacturing facility here in Hopewell, N.J., will help expedite bringing these therapies to patients,” said Li Chen, CEO of ProBio Inc. “This expansion underscores our commitment to accelerating the delivery of advanced therapies to patients.”
 
“The Hopewell facility exemplifies our mission to bring innovative therapies from concept to reality,” commented Patrick Liu, Chairman of ProBio Inc. “By enhancing our capabilities, we not only support the rapid development of novel treatments but also ensure that these therapies reach patients more efficiently and effectively.”
 
The facility’s cGMP suites will undergo renovation to produce plasmid DNA and viral vectors for phase-appropriate programs, enhancing the company’s capabilities and reinforcing its position in the biotech sector.